| Literature DB >> 28416546 |
Darya Starosila1, Svetlana Rybalko1, Ludmila Varbanetz2, Naila Ivanskaya1, Iryna Sorokulova3.
Abstract
Among Bacillus bacteria, B. subtilis is the species that produces the most antimicrobial compounds. In this study, we analyzed the activity of probiotic strain B. subtilis 3 against the influenza virus. The antiviral effect of this strain has been demonstrated in vitro and in vivo A new peptide, P18, produced by the probiotic strain was isolated, purified, chemically synthesized, and characterized. Cytotoxicity studies demonstrated no toxic effect of P18 on Madin-Darby canine kidney (MDCK) cells, even at the highest concentration tested (100 μg/ml). Complete inhibition of the influenza virus in vitro was observed at concentrations of 12.5 to 100 μg/ml. The protective effect of P18 in mice was comparable to that of oseltamivir phosphate (Tamiflu). Further study will assess the potential of peptide P18 as an antiviral compound and as a promising candidate for the development of new antiviral vaccines.Entities:
Keywords: Bacillus subtilis; antiviral peptide; influenza virus; probiotics
Mesh:
Substances:
Year: 2017 PMID: 28416546 PMCID: PMC5487639 DOI: 10.1128/AAC.00539-17
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191